ADAPTIVE-CONTROL WITH FEEDBACK-STRATEGIES FOR SURAMIN DOSING

被引：42

作者：

COOPER, MR ^{[1
]}

LIEBERMAN, R ^{[1
]}

LAROCCA, RV ^{[1
]}

GERNT, PR ^{[1
]}

WEINBERGER, MS ^{[1
]}

HEADLEE, DJ ^{[1
]}

KOHLER, DR ^{[1
]}

GOLDSPIEL, BR ^{[1
]}

PECK, CC ^{[1
]}

MYERS, CE ^{[1
]}

机构：

[1] US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 1992年 / 52卷 / 01期

关键词：

D O I：

10.1038/clpt.1992.97

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Suramin, a drug used in the treatment of parasitic diseases, is currently being evaluated in clinical trials as an antineoplastic agent. The use of therapeutic drug monitoring and adaptive control with feedback in clinical trials of suramin was initially motivated by an association between acute neurologic toxicity and plasma suramin concentrations in excess of 350-mu-g/ml. We have prospectively examined the performance of both two- and three-compartment population pharmacokinetic models in controlling plasma suramin concentrations and have found that a three-compartment model best describes this drug. No correlation was found between the clearance of suramin and creatinine clearance, as had been previously hypothesized. The low systemic clearance of suramin and the number of parameters required to describe the three-compartment model suggest the need for a bayesian approach to the estimation of individual pharmacokinetics.

引用

页码：11 / 23

页数：13

共 41 条

[1]

BEAL S, 1979, NONMEM USERS GUIDE 1

[2] EFFICIENT REVERSION OF SIMIAN SARCOMA VIRUS-TRANSFORMATION AND INHIBITION OF GROWTH FACTOR-INDUCED MITOGENESIS BY SURAMIN [J].